That's certainly a valid criticism.
They received a unanimous recommendation to continue the trial by the DMSB after the second interim readout and have the third interim readout due in the next couple of weeks, so we should soon see if there is still a gap between the treatment and placebo arms (evidence of efficacy) in their P2/P3 Covid trial.
That's certainly a valid criticism. They received a unanimous...
Add NOX (ASX) to my watchlist
 (20min delay)
|
|||||
|
Last
11.0¢ |
Change
0.005(4.76%) |
Mkt cap ! $32.14M | |||
| Open | High | Low | Value | Volume |
| 11.5¢ | 11.5¢ | 11.0¢ | $18.94K | 171.9K |
Buyers (Bids)
| No. | Vol. | Price($) |
|---|---|---|
| 1 | 50000 | 11.0¢ |
Sellers (Offers)
| Price($) | Vol. | No. |
|---|---|---|
| 12.5¢ | 66800 | 1 |
View Market Depth
| Last trade - 14.48pm 08/11/2024 (20 minute delay) ? |
| NOX (ASX) Chart |